Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.36 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031763 | 0.85 | MAOB (0.56) | MAOBPTGESCYP19A1MEN1KMT2A | |
| SCHEMBL12539779 | 0.84 | BACE1 (0.56) | MAOBMEN1KMT2AAPP | |
| SCHEMBL15459156 | 0.75 | APP (0.36) | MAOBTRPV4CYP19A1MEN1KMT2A | |
| SCHEMBL11178136 | 0.74 | MAOB (0.53) | MAOBCYP19A1MEN1KMT2AIMPDH2 | |
| SCHEMBL15459130 | 0.74 | APP (0.39) | MAOBPTGESMEN1KMT2AIMPDH2 | |
| SCHEMBL11407178 | 0.73 | IMPDH2 (0.50) | MAOBPTGESCYP19A1MEN1KMT2A | |
| SCHEMBL25891284 | 0.73 | VKORC1 (0.54) | MAOBCYP19A1MEN1KMT2AIMPDH2 | |
| SCHEMBL12744505 | 0.72 | ERBB2 (0.40) | HPGD | |
| SCHEMBL10738991 | 0.72 | IMPDH2 (0.42) | MAOBIMPDH2APP | |
| SCHEMBL16597206 | 0.70 | ERBB2 (0.39) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028914-B2 | Reduction type coenzyme Q10 powder, composition thereof, and preparation method thereof | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutica Factory (CN) | 2018-07-24 | — | — | US | disclosed |
| US-20170209463-A1 | DIETARY SUPPLEMENT COMPOSITIONS FOR CARDIOVASCULAR HEALTH | MELALEUCA, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20160101053-A1 | Reduction Type Coenzyme Q10 Powder, Composition Thereof, And Preparation Method Thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2016-04-14 | — | — | US | disclosed |
| US-20110038848-A1 | DIETARY SUPPLEMENT COMPOSITIONS FOR CARDIOVASCULAR HEALTH | MELALEUCA, INC. (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209463-A1 | DIETARY SUPPLEMENT COMPOSITIONS FOR CARDIOVASCULAR HEALTH | APOB, FABP3, HDLBP | MAOB 1439/4885PTGES 1834/4885TRPV4 4739/4885 |
| US-20160101053-A1 | Reduction Type Coenzyme Q10 Powder, Composition Thereof, And Preparation Method Thereof | NDUFA10, NDUFB10, COQ8A | MAOB 828/4885PTGES 415/4885TRPV4 4447/4885 |
| US-10028914-B2 | Reduction type coenzyme Q10 powder, composition thereof, and preparation method thereof | NDUFA10, NDUFB10, COQ8A | MAOB 828/4885PTGES 415/4885TRPV4 4447/4885 |
| US-20110038848-A1 | DIETARY SUPPLEMENT COMPOSITIONS FOR CARDIOVASCULAR HEALTH | APOB, FABP3, HDLBP | MAOB 1439/4885PTGES 1834/4885TRPV4 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.